In an interview with the International Business Times, Dr. Stuart Titus revealed how RSHO-X™ helped spark cannabis reform in Mexico and what the next steps are for the worldwide cannabis industry.
A comprehensive article published on the International Business Times (IBT) this week covered the changing global attitudes toward marijuana, specifically in Mexico and the U.S., before featuring an interview with Dr. Stuart Titus, CEO of Medical Marijuana, Inc.
In the interview, Dr. Titus talks about the earliest stages of the CBD oil industry and Medical Marijuana, Inc.’s pioneering role in establishing the technology and manufacturing standards that are used widely today. Dr. Titus also discusses the roadblocks companies like Medical Marijuana, Inc. have faced and continue to overcome in the development of a global CBD market, including the need for further clinical research and the negative preconceptions of some lawmakers. [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_single_image image=”17975″ img_size=”1200×250″ onclick=”custom_link” link=”https://www.medicalmarijuanainc.com/what-is-cannabidiol/”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]“Unfortunately, change in the medical society is very slow, especially here in the U.S…. basically doctors and the medical community are very much wanting to see the hard clinical evidence. And so far we’ve only been able to do early stage preclinical work funded by government and national institutes through health grants,” said Dr. Titus. “Trying to get human testing has really been a challenge to get through the regulatory parties. Human studies with cannabis-based products need FDA approval. You need DEA approval, so there’s a lot of hoops to jump through.”
However, shifting viewpoints on cannabis are leading to policy changes around the globe, and in countries like Mexico, where positions on marijuana have long been contradictory, we are starting to see a move toward more progressive cannabis strategies thanks to the spread of non-psychoactive products like CBD hemp oil.
“We’re certainly excited about the fact that regulatory parties there seem to be much more progressive. They understand now that non-psychoactive CBD has a tremendous potential place in terms of these very difficult to treat conditions,”mentioned Dr. Titus. “This is something that’s helping move the overall cannabis space and legislation and helping to improve the dialogue that certainly is existing.”
Dr. Titus and Medical Marijuana, Inc. are working hard to expand awareness of cannabis’s potential, and interviews like Dr. Titus’s in IBT this week assist in spreading our important message of increased access to cannabinoids like CBD for everyone.
“We are always excited to work with publications like the International Business Times and help spread the word about Medical Marijuana, Inc.’s goals to help those all over the globe who have been suffering for so long,” remarked Dr. Titus of the interview. “We are glad that countries like Mexico are starting to understand that non-psychoactive CBD has tremendous potential for their people. Our organization looks forward to initiating further research to demonstrate the potential benefits for the medical and scientific community – in directions where our anecdotal evidence points us.”